Article

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

2021-10-10

Abstract excerpt

<h4>BACKGROUND</h4> Vaccination using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein antigen has been effective in the prevention of coronavirus disease 2019 (Covid-19). NVX-CoV2373 is an adjuvanted, recombinant S protein nanoparticle vaccine that demonstrated clinical efficacy for prevention of Covid-19 in phase 2b/3 trials in the United Kingdom and South Africa. <h4>METHODS</h4>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cd0b8e01-0328-5b48-8d14-88e009ababec
DOI: 10.1101/2021.10.05.21264567

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoDOI 10.1101/2021.10.05.21264567Read

NVX-CoV2373 Vaccine Efficacy Against Hospitalization: A<i>post hoc</i>analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trialSemantic proximity Read

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialSemantic proximity Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adultsSemantic proximity Read

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity Read

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 VariantSemantic proximity Read

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)Semantic proximity Read

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03Semantic proximity Read

Efficacy and Safety of an Inactivated Whole-Virion SARS-CoV-2 Vaccine (CoronaVac) in Brazilian Healthcare Professionals: The PROFISCOV TrialSemantic proximity Read